Spanish firm Zenosense and its UK-based joint venture (JV) MIDS Medical have commenced the evaluation of the Hybrid Strip system to capture data from low doses of nanoparticles and microbeads.

Hybrid Strip is a simulation of MIDS Lab-on-Chip (LoC) test strip system being developed to validate the LoC nano-magnetic detection of paramagnetic nanoparticles quantities that are highly sensitive and assay-sized.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The system features a micromachined, plasma-coated plastic strip consisting of a microfluidic channel to allow the flow of fluid-entrained nanoparticles and microbeads into an area designed for magnetic entrapment and detection.

MIDS Medical has developed the Hybrid Strip system in collaboration with a European biomedical microfluidics manufacturer.

The flow testing of the microfluidic strip is intended to ensure the performance of its channel geometry.

“Upon successful completion of testing of the MIDS nano-magnetic detection system, it is expected to enable point-of-care (POC) high-sensitivity troponin testing and new POC immunoassay tests.”

The strip further includes Hall Effect sensors on a flexible circuit board and a 3D-printed magnet holder assembly to generate the required magnetic field for moving and entrapping the nanoparticles.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Upon successful completion of testing of the MIDS nano-magnetic detection system, it is expected to enable point-of-care (POC) high-sensitivity troponin testing and new POC immunoassay tests.

Zenosense develops and markets medical devices for early detection of bacteria and specific cancers in the exhaled breath of patients at hospitals and primary healthcare settings.

The firm’s flagship product is a handheld, POC device called MIDS Cardiac developed for rapid diagnosis, treatment and disposition of patients with chest pain and suspected acute myocardial infarction.